

Boston Scientific

## **Boston Scientific Announces Availability of Advanced Feature in Company's Heart Failure Devices**

**Thousands of Heart Failure Patients Are Now Eligible for Additional Pacing Feature**

PRNewswire-FirstCall  
NATICK, Mass.  
(NYSE:BSX)

NATICK, Mass., Nov. 1 /[PRNewswire-FirstCall](#)/ -- Boston Scientific Corporation (NYSE: BSX) today announced the launch of software enabling its Left Ventricular (LV) Offset feature in the Company's CONTAK RENEWAL®, RENEWAL 3, and RENEWAL 3 RF cardiac resynchronization therapy defibrillators (CRT-D). LV Offset allows physicians to further fine tune synchronization of the heart by allowing adjustment of the delay between right and left ventricular pacing, which helps physicians provide more tailored care for heart failure patients.

"The LV Offset capability provides yet another tool to better meet the specific treatment needs of each of my heart failure patients," said David B. DeLurgio, M.D., Director, Electrophysiology, Emory Crawford Long Hospital in Atlanta, GA.

The software will operate on the ZOOM® LATITUDE™ programmer and allow patients who have already been implanted with a CONTAK RENEWAL, RENEWAL 3 or RENEWAL 3 RF CRT-D to have the LV Offset feature activated. The LV Offset feature can be enabled by the ZOOM LATITUDE programmer during a patient's routine in-clinic visit. Boston Scientific CRM will begin providing the FDA- approved software to physicians in the coming weeks.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: <http://www.bostonscientific.com/>.

This press release contains forward-looking statements. Boston Scientific wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, integration of acquired companies, Boston Scientific's overall business strategy, and other factors described in Boston Scientific's filings with the Securities and Exchange Commission.

SOURCE: Boston Scientific Corporation

CONTACT: Milan Kofol, +1-508-650-8569 (office), or +1-617-834-8595 (mobile), Investor Relations; or Paul Donovan, +1-508-650-8541 (office), or +1-508-667-5165 (mobile), Media Relations, both of Boston Scientific Corporation

Web site: <http://www.bostonscientific.com/>

---

<https://news.bostonscientific.com/news-releases?item=58906>